The Division of Hematology/Oncology is actively involved in clinical, academic, and healthcare delivery research. We are all members of the Children’s Oncology Group (international) and currently have more than 50 therapeutic and biology studies open at CHEO.

The division is involved in research that includes:


  • Children’s Oncology Group: there are 12 therapeutic, 10 biology studies and 5 supportive care studies open at CHEO
  • Study of low-dose metronomic topotecan and pazopanib in pediatric patients with recurrent or refractory solid tumors
  • Evaluation of the efficacy and safety of rivipansel in the treatment of vaso occlusive crisis in sickle cell pediatric patients
  • Mutations in dysplasias, dysontogenic disease, tumors and other conditions
  • Improving quality of life in children with cancer through psychosocial screening and improved communication
  • Initiative to maximize progress in adolescent cancer therapy
  • Adrenal insufficiency in children with ALL during treatment
  • Assessment of respiratory disability in adult survivors of childhood cancer
  • Exploring the feasibility, safety and potential benefits of a 12-week home-based physical activity intervention for children with cancer
  • Vaccinating children after chemotherapy for ALL: a Canadian immunization research network study
  • Very long term neurocognitive and endocrine outcomes of childhood cancer survivors
  • Perspectives on investigational fertility preservation techniques
  • Validation of self-administered pediatric bleeding tool
  • Central venous line dysfunction as a predictor of thromboembolism in children with cancer
  • Exploring young cancer survivor-parent dyads perceptions of social support to engage in physical activity
  • Oral rivaroxaban in venous thrombosis
  • Applying biomarkers to long term effects of childhood cancer treatment
  • Dabigatran anticoagulant therapy
  • Osteonecrosis in children with acute lymphoblastic leukemia
  • Dose finding study of melatonin in children with relapsed solid tumors
  • Inherited bone marrow failure syndromes
  • Idiopathic thrombocytopenic purpura (ITP) quality of life instrument
  • Thalassemia major quality of life instrument for pediatric and adults
  • Myelodysplasia-specific quality of life instrument
  • Blood borne pathogens surveillance project
  • ITP therapy with intravenous immunoglobulin (IVIG) versus IVIG with steroids
  • Prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer
  • Canadian hemophilia database (CHARMS)
  • National sickle cell registry


  • Impact of eConsultation in pediatric specialty referral process
  • Impact of newborn screening on the rates of hemoglobinopathies and disease-related complications among children in Ontario
  • Syrian refugees and their effects on healthcare services across Canada
  • Physician treatment decisions and patient-reported outcomes in ITP
  • Assessing and supporting the physical literacy of Ontario children with medical conditions and disabilities
  • The effect of “Pathway” to diagnosis for childhood ITP on initial health-related quality of life
  • Enrollment of adolescent and young adults with cancer to clinical trials
  • Creating a validated algorithm for the identification of immigrant children with hemoglobinopathies in Ontario
  • Electronic pain diary for youths with cancer
  • Transition to meaningful activity for childhood cancer survivors
  • Development and usability of an online self-management and transitional care program for youth with cancer


  • Evaluating the resident experience in the learning environment

Related Links

Back to top